Literature DB >> 31949123

Prognostic Value of Pre-Infarction Angina Combined with Mean Platelet Volume to Lymphocyte Count Ratio for No-Reflow and Short-Term Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.

Xinsen Chen1, Youbao Meng2, Meng Shao3, Tian Zhang1, Ling Han3, Wei Zhang1, Hongyan Zhang1, Hua Hai1, Guihua Li1.   

Abstract

<strong>BACKGROUND</strong> The aim of the present study was to investigate the clinical predictive value of pre-infarction angina (PIA) combined with mean platelet volume to lymphocyte count ratio (MPVLR) for no-reflow phenomenon and short-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). <strong>MATERIAL AND METHODS</strong> A total of 1009 STEMI patients who had undergone PCI were enrolled and subdivided into 4 groups based on the occurrence of PIA and the presence of MPVLR above or below the cutoff value. Analysis of the predictors of the no-reflow phenomenon and 90-day mortality was conducted. Further, evaluation and comparison of the clinical predictive value of PIA, MPVLR, and their combination were done. <strong>RESULTS</strong> Both MPVLR (odds ratio [OR]=1.476, 95% confidence interval [CI]: 1.401 to 1.756, <i>P</i><0.001; hazard ratio [HR]=1.430, 95% CI: 1.287 to 1.643, <i>P</i><0.001) and PIA (OR=0.905, 95% CI: 0.783 to 0.986, <i>P</i><0.001; HR=0.878, 95% CI: 0.796 to 0.948, <i>P</i><0.001) were independent predictors of no-reflow phenomenon and 90-day mortality. Spearman's rank correlation test revealed that MPVLR (r=-0.297, <i>P</i><0.001), monocyte to lymphocyte count ratio (MLR) (r=-0.211, <i>P</i><0.001) and neutrophil to lymphocyte count ratio (NLR) (r=-0.389, <i>P</i><0.001) in peripheral blood were significantly negatively correlated with postoperative left ventricular ejection fraction (LVEF). Upon comparing the area under curve (AUC), the MPVLR combined with PIA achieved better performance in differentiating no-reflow phenomenon (AUC=0.847, 95% CI: 0.821 to 0.874) and 90-day mortality (AUC=0.790, 95% CI: 0.725 to 0.855), than the GRACE score, MPVLR and PIA alone, and had similar performance to all other pairwise combinations of the GRACE score, MPVLR and PIA. <strong>CONCLUSIONS</strong> High MPVLR and PIA were independent predictors of the no-reflow phenomenon and 90-day mortality in patients with STEMI after PCI. Moreover, Combined application of MPVLR and PIA can effectively predict the occurrence of the no-reflow phenomenon and 90-day mortality.

Entities:  

Year:  2020        PMID: 31949123     DOI: 10.12659/MSM.919300

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  4 in total

1.  Prognostic Value of the Leuko-Glycemic Index in Acute Myocardial Infarction Patients with or without Diabetes.

Authors:  Ling-Yao Qi; Han-Xiong Liu; Lian-Chao Cheng; Yan Luo; Si-Qi Yang; Xu Chen; Lin Cai
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-09       Impact factor: 3.249

2.  Machine learning to predict no reflow and in-hospital mortality in patients with ST-segment elevation myocardial infarction that underwent primary percutaneous coronary intervention.

Authors:  Lianxiang Deng; Xianming Zhao; Xiaolin Su; Mei Zhou; Daizheng Huang; Xiaocong Zeng
Journal:  BMC Med Inform Decis Mak       Date:  2022-04-24       Impact factor: 3.298

3.  Retrospective Study of Clinical Features of COVID-19 in Inpatients and Their Association with Disease Severity.

Authors:  Hao Wang; Yang Xing; Xiaohong Yao; Yang Li; Jietao Huang; Jun Tang; Shasha Zhu; Ying Zhang; Jun Xiao
Journal:  Med Sci Monit       Date:  2020-12-21

4.  Changes in the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios before and after percutaneous coronary intervention and their impact on the prognosis of patients with acute coronary syndrome.

Authors:  Jianlong Sheng; Nina Liu; Fei He; Cheng Cheng; Shichun Shen; Yuting Sun
Journal:  Clinics (Sao Paulo)       Date:  2021-08-04       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.